Acute tumour lysis syndrome: a case in AL amyloidosis.
Tumour lysis syndrome (TLS) in plasma cell dyscrasias is extremely rare. TLS has been described in eight cases of multiple myeloma undergoing high-dose therapy with autologous stem cell transplant (ASCT). Recently, clinical trials of intensive chemotherapy followed by autologous or allogeneic stem cell support has been shown to offer potential benefit in AL (amyloid light-chain) amyloidosis. TLS in primary AL amyloidosis in this setting has not been previously reported. We report a case of TLS in a patient with AL amyloidosis which developed after high-dose melphalan chemotherapy supported by ASCT.
Akasheh
M S
MS
Bone Marrow Transplant Unit, Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA. makasheh@mcw.edu
Chang
C P
CP
Vesole
D H
DH
D000208:Acute Disease; D000368:Aged; D000686:Amyloidosis / Q000628:therapy*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000009:adverse effects*; D015275:Tumor Lysis Syndrome / Q000209:etiology*
D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan